[HTML][HTML] The utility of conventional amino acid PET radiotracers in the evaluation of glioma recurrence also in comparison with MRI

G Santo, R Laudicella, F Linguanti, AG Nappi… - Diagnostics, 2022 - mdpi.com
Aim: In this comprehensive review we present an update on the most relevant studies
evaluating the utility of amino acid PET radiotracers for the evaluation of glioma recurrence …

[HTML][HTML] Tumor progression and treatment-related changes: Radiological diagnosis challenges for the evaluation of post treated glioma

D Qin, G Yang, H Jing, Y Tan, B Zhao, H Zhang - Cancers, 2022 - mdpi.com
Simple Summary Glioma is the most common primary malignant tumor of the adult central
nervous system. Despite aggressive multimodal treatment, its prognosis remains poor …

[HTML][HTML] The value of FET PET/CT in recurrent glioma with a different IDH mutation status: the relationship between imaging and molecular biomarkers

M Skoblar Vidmar, A Doma, U Smrdel, K Zevnik… - International Journal of …, 2022 - mdpi.com
The evaluation of treatment response remains a challenge in glioma cases because the
neuro oncological therapy can lead to the development of treatment-related changes (TRC) …

[HTML][HTML] The Use of 18F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds—A Narrative Review

T van de Weijer, MPG Broen, RPM Moonen, A Hoeben… - Diagnostics, 2022 - mdpi.com
Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-
IV astrocytomas and grade II-III oligodendrogliomas, based on their histomolecular profile …

Novel Positron-Emitting Radiopharmaceuticals

O Keinänen, AG Nash, SM Sarrett… - Nuclear Oncology: From …, 2022 - Springer
In recent decades, radiopharmaceuticals–particularly those for PET imaging–have become
vital clinical tools in oncology. In this chapter, we seek to provide a bird's-eye view of the …